MOR102
MOR102 is a fully human IgG4 monoclonal antibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3. MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Fab-G4-nd
Human
MOR102 (0.04-10 μg/mL; 30 min) potently inhibits adhesion of human SKW-3 T-cell leukaemia cells to immobilized recombinant ICAM-1 with an IC50 of 3 nM[1].
MOR102 (0.5-50 μg/mL; 4 days) reduces proliferation of human peripheral blood mononuclear cells in mixed lymphocyte cultures[1].
MOR102 (10 μg/mL; overnight) binds to human HaCaT keratinocytes, with increased binding observed on IFN-γ-stimulated HaCaT cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MOR102 (10 mg/kg; i.p.; every other day; 4 weeks) induces orthokeratotic differentiation, reduces epidermal thickness, and decreases inflammatory infiltrate in human chronic plaque-stage psoriasis skin grafts on SCID mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B17 SCID mice (6-8 weeks old) transplanted with human split skin grafts[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every alternate day; 4 weeks from day 22-50 after transplantation
-
Result:Reduced mean epidermal thickness to 255 μm, a significant reduction compared to control.
Reduced mean inflammatory infiltrate density to 136 cells per high-power field, a marked reduction compared to PBS-treated controls.
Induced reconstitution of orthokeratotic differentiation of the epidermis, with moderate acanthosis, mild papillomatosis, a web-like corneal layer with mild remaining parakeratosis, and a re-established granular layer.
Demonstrated intense staining of keratinocytes in grafts via immunohistochemistry, confirming targeting of ICAM-1 on keratinocytes.
-
Animal Model:SCID mice transplanted with human split skin grafts[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; 4 weeks
-
Result:Reconstituted orthokeratotic differentiation of the transplanted skin.
Significantly reduced epidermal thickness.
Markedly reduced the inflammatory infiltrate within the graft.
ICAM1/CD54
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Boehncke WH, et al. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005;153(4):758-766. [Content Brief]
[2]. Mrowietz U, et al. Leukocyte adhesion: a suitable target for anti-inflammatory drugs. Curr Pharm Des. 2006;12(22):2825-2831. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz